Tevogen (TVGN) Net Cash Flow (2022 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Net Cash Flow came in at $139933.0 in Q1 2026, down 79.78% YoY from $691937.0 in Q1 2025, and up 133.29% on a QoQ basis from -$420283.0 in Q4 2025.
Tevogen (TVGN) Net Cash Flow (2022 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 5 years of Net Cash Flow data on file, last reported at $139933.0 in Q1 2026.
- Quarterly Net Cash Flow fell 79.78% year-over-year to $139933.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 million (down 285.41% YoY) and the FY2025 annual result came in at -$730623.0, down 416.84% from the prior year.
- Net Cash Flow grew to $139933.0 in Q1 2026, from -$420283.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $1.2 million in Q3 2024 to a low of -$2.2 million in Q2 2023.
- A 5-year average of -$290759.8 and a median of -$45901.0 in 2022 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 267.97% in 2023, down 11112.91% in 2023.
- Tracing TVGN's Net Cash Flow over 5 years: stood at -$13861.0 in 2022, then tumbled by 11112.91% to -$1.6 million in 2023, then soared by 32.59% to -$1.0 million in 2024, then soared by 59.88% to -$420283.0 in 2025, then surged by 133.29% to $139933.0 in 2026.
- The last three Net Cash Flow figures came in at $139933.0 (Q1 2026), -$420283.0 (Q4 2025), and $351865.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 139,933.00 |
| Mar 31, 2026 | 139,933.00 |
| Dec 31, 2025 | -420,283.00 |
| Dec 31, 2025 | -420,283.00 |
| Sep 30, 2025 | 351,865.00 |
| Sep 30, 2025 | 351,865.00 |
| Jun 30, 2025 | -1.29 Mn |
| Jun 30, 2025 | -1.29 Mn |
| Mar 31, 2025 | 691,937.00 |
| Mar 31, 2025 | 691,937.00 |
| Dec 31, 2024 | -1.05 Mn |
| Dec 31, 2024 | -1.05 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | -182,510.00 |
| Jun 30, 2024 | -182,510.00 |
| Mar 31, 2024 | 265,503.00 |
| Mar 31, 2024 | 265,503.00 |
| Dec 31, 2023 | -1.55 Mn |
| Dec 31, 2023 | -1.55 Mn |